NCT01659411 is a clinical trial of Observational in Pulmonary Arterial Hypertension, sponsored by Actelion.

Who is sponsoring NCT01659411?

NCT01659411 is sponsored by Actelion.

What drugs are being tested in NCT01659411?

Interventions in NCT01659411: Observational.

What condition does NCT01659411 study?

NCT01659411 studies Pulmonary Arterial Hypertension.

Is NCT01659411 still recruiting?

NCT01659411 is currently completed. Last updated 3 February 2025.

Last reviewed 2025-02-03 · How we verify

NCT01659411

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adult Congenital Heart Disease Registry (QuERI)

Completed Last updated 3 February 2025

What this trial tests

trial testing Observational in Pulmonary Arterial Hypertension in 217 participants. Completed in 16 May 2018.

Timeline

1 December 2011

Primary endpoint
16 May 2018

16 May 2018

Quick facts

Lead sponsor	Actelion
Status	Completed
Study type	OBSERVATIONAL
Enrollment	217
Start date	1 December 2011
Primary completion	16 May 2018
Estimated completion	16 May 2018

Drugs / interventions tested

Observational — full drug profile →

Conditions studied

Pulmonary Arterial Hypertension — all drugs for Pulmonary Arterial Hypertension →

Sponsor

Actelion — full company profile →

Who can join

18 and older, any sex, with Pulmonary Arterial Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multi-center, observational, U.S.-based longitudinal program. Data will be collected prospectively for 3 years. Individual physician feedback will be provided on data collected with the purpose of improving the management of patients - quality enhancement research initiative (QuERI) process from adult patients enrolled with a history of repaired Congenital Heart Disease (CHD).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The Changing Landscape of Pulmonary Arterial Hypertension in the Adult with Congenital Heart Disease.
van Dissel AC, Mulder BJ, Bouma BJ. · · 2017 · cited 11× · PMID 28358329 · DOI 10.3390/jcm6040040
Timely PAH Identification in Adults With Repaired Congenital Heart Disease? The ACHD-QuERI Registry Insights.
Landzberg MJ, Daniels CJ, Forfia P, McLaughlin VV, et al · · 2023 · cited 1× · PMID 38938704 · DOI 10.1016/j.jacadv.2023.100649
Timely PAH Identification in Adults With Repaired Congenital Heart Disease? The ACHD-QuERI Registry Insights
Landzberg M, Daniels C, Forfia P, McLaughlin V, et al · · 2023

Verify or expand the search:

Other trials of Observational

Trials testing the same drug.

NCT07356700 — Deciphering the Factors of Longevity Through a Multi-Omics Study in Long-Lived Individuals in Hong Kong · not yet recruiting
NCT07381751 — Artificial Intelligence-assisted MDS-UPDRS Assessment for Parkinson's Disease · not yet recruiting
NCT07347574 — NeuroCare Community Project: A Community Based Prospective Observational Study for Early Alzheimer's Detection in HK · not yet recruiting
NCT07338968 — A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma · not yet recruiting
NCT06792994 — A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients Wi · not yet recruiting

Other recruiting trials for Pulmonary Arterial Hypertension

Currently open trials in the same condition.

NCT07391228 — Cognitive Alterations in Pulmonary Arterial Hypertension (PAH) · active not recruiting
NCT06351345 — 129 Xenon Imaging in Patients Treated With Sotatercept · Phase 2 · recruiting
NCT07217522 — Rutgers University Study of the Genetics of Pulmonary Hypertension · recruiting
NCT07013149 — The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension · recruiting
NCT06658522 — Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effec · Phase 4 · recruiting

Other Actelion trials

Trials by the same sponsor.

NCT05731492 — A Study of Macitentan in Children Below 2 Years of Age · Phase 1 · withdrawn
NCT05433675 — A Study of Two Macitentan Formulations in Healthy Adult Participants · Phase 1 · completed
NCT05427162 — A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist · Phase 1 · completed
NCT05392530 — A Study of Two Different Test Formulations Compared to the Reference Formulation of Macitentan in Healthy Adult Particip · Phase 1 · completed
NCT05179876 — A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no O · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01659411 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Actelion
Last refreshed: 3 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01659411.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing